IL166423A0 - Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies - Google Patents
Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapiesInfo
- Publication number
- IL166423A0 IL166423A0 IL16642303A IL16642303A IL166423A0 IL 166423 A0 IL166423 A0 IL 166423A0 IL 16642303 A IL16642303 A IL 16642303A IL 16642303 A IL16642303 A IL 16642303A IL 166423 A0 IL166423 A0 IL 166423A0
- Authority
- IL
- Israel
- Prior art keywords
- erb
- kinase inhibitors
- therapeutic combinations
- antineoplastic therapies
- antineoplastic
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40170502P | 2002-08-07 | 2002-08-07 | |
| US46224703P | 2003-04-11 | 2003-04-11 | |
| PCT/IB2003/003388 WO2004014386A1 (en) | 2002-08-07 | 2003-07-28 | Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL166423A0 true IL166423A0 (en) | 2006-01-15 |
Family
ID=31720553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16642303A IL166423A0 (en) | 2002-08-07 | 2003-07-28 | Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040067942A1 (pl) |
| EP (1) | EP1549320A1 (pl) |
| JP (1) | JP2005538129A (pl) |
| CN (1) | CN1674908A (pl) |
| AR (1) | AR040792A1 (pl) |
| AU (1) | AU2003249450A1 (pl) |
| BR (1) | BR0313470A (pl) |
| CA (1) | CA2494270A1 (pl) |
| IL (1) | IL166423A0 (pl) |
| MX (1) | MXPA05001430A (pl) |
| NO (1) | NO20051170L (pl) |
| PA (1) | PA8578001A1 (pl) |
| PE (1) | PE20040990A1 (pl) |
| PL (1) | PL375414A1 (pl) |
| RU (1) | RU2005102836A (pl) |
| TW (1) | TW200404532A (pl) |
| WO (1) | WO2004014386A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US7695731B2 (en) * | 2004-03-22 | 2010-04-13 | Cordis Corporation | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| BRPI0509732A (pt) | 2004-04-09 | 2007-09-25 | Chugai Pharmaceutical Co Ltd | pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco |
| RS52119B (sr) | 2004-05-06 | 2012-08-31 | Warner-Lambert Company Llc | 4-fenilamino-hinazolin-6-il-amidi |
| JP2008501654A (ja) * | 2004-06-03 | 2008-01-24 | エフ．ホフマン−ラ ロシュ アーゲー | シスプラチンとｅｇｆｒ阻害剤を用いた治療 |
| AU2005249205A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with gemcitabine and an EGFR-inhibitor |
| EP1761264A1 (en) * | 2004-06-03 | 2007-03-14 | F.Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
| CN1984656B (zh) * | 2004-06-04 | 2010-05-26 | 史密丝克莱恩比彻姆（科克）有限公司 | 癌症治疗药物 |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| WO2007139930A2 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| RU2325199C2 (ru) * | 2006-06-20 | 2008-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| RU2480211C2 (ru) * | 2007-11-12 | 2013-04-27 | Байпар Сайенсиз, Инк. | Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами |
| MX2013012995A (es) * | 2011-05-06 | 2014-07-09 | Merrimack Pharmaceuticals Inc | Metodos para prevenir interacciones farmaco-farmaco toxicas en terapias de combinacion que comprenden agentes anti-erbb3. |
| TW202143965A (zh) * | 2020-03-06 | 2021-12-01 | 美商迪賽孚爾製藥有限公司 | 使用瑞巴替尼（ｒｅｂａｓｔｉｎｉｂ）治療病症之方法 |
| CN118576611A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗尤文氏肉瘤的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287223B1 (en) * | 1997-04-11 | 2001-09-11 | Liechty, Ii Victor Jay | Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| WO2002055106A2 (en) * | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
-
2003
- 2003-07-22 PA PA20038578001A patent/PA8578001A1/es unknown
- 2003-07-28 BR BR0313470-9A patent/BR0313470A/pt not_active IP Right Cessation
- 2003-07-28 IL IL16642303A patent/IL166423A0/xx unknown
- 2003-07-28 CN CNA038191180A patent/CN1674908A/zh active Pending
- 2003-07-28 CA CA002494270A patent/CA2494270A1/en not_active Abandoned
- 2003-07-28 WO PCT/IB2003/003388 patent/WO2004014386A1/en not_active Ceased
- 2003-07-28 RU RU2005102836/14A patent/RU2005102836A/ru not_active Application Discontinuation
- 2003-07-28 PL PL03375414A patent/PL375414A1/pl not_active Application Discontinuation
- 2003-07-28 MX MXPA05001430A patent/MXPA05001430A/es unknown
- 2003-07-28 JP JP2004527183A patent/JP2005538129A/ja not_active Withdrawn
- 2003-07-28 EP EP03784371A patent/EP1549320A1/en not_active Withdrawn
- 2003-07-28 AU AU2003249450A patent/AU2003249450A1/en not_active Abandoned
- 2003-08-01 US US10/632,281 patent/US20040067942A1/en not_active Abandoned
- 2003-08-04 PE PE2003000768A patent/PE20040990A1/es not_active Application Discontinuation
- 2003-08-05 AR AR20030102806A patent/AR040792A1/es unknown
- 2003-08-06 TW TW092121515A patent/TW200404532A/zh unknown
-
2005
- 2005-03-04 NO NO20051170A patent/NO20051170L/no unknown
-
2006
- 2006-08-14 US US11/464,249 patent/US20060293323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PA8578001A1 (es) | 2004-05-07 |
| MXPA05001430A (es) | 2005-06-06 |
| PE20040990A1 (es) | 2004-12-27 |
| RU2005102836A (ru) | 2005-08-10 |
| US20060293323A1 (en) | 2006-12-28 |
| CA2494270A1 (en) | 2004-02-19 |
| WO2004014386A1 (en) | 2004-02-19 |
| EP1549320A1 (en) | 2005-07-06 |
| US20040067942A1 (en) | 2004-04-08 |
| CN1674908A (zh) | 2005-09-28 |
| AR040792A1 (es) | 2005-04-20 |
| TW200404532A (en) | 2004-04-01 |
| AU2003249450A1 (en) | 2004-02-25 |
| PL375414A1 (pl) | 2005-11-28 |
| NO20051170L (no) | 2005-05-06 |
| BR0313470A (pt) | 2005-06-21 |
| JP2005538129A (ja) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL166423A0 (en) | Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies | |
| EP1539129A4 (en) | DOSAGE FORMS AND RELEVANT THERAPIES | |
| PL403456A1 (pl) | Pochodne 5-fenylotiazolu oraz ich zastosowanie jako inhibitorów kinazy Pi3 | |
| HRP20041029A2 (en) | Therapeutic use of selcetive pde10 inhibitors | |
| IL176233A0 (en) | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | |
| AU2003256410A8 (en) | Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions | |
| AU2003303128A8 (en) | Inhibitors and methods of use thereof | |
| PH12012501372A1 (en) | Proteasome inhibitors and methods of using the same | |
| PL372620A1 (pl) | Nowe kompozycje farmaceutyczne na bazie antycholinergików oraz inhibitorów kinazy p38 | |
| PL374598A1 (pl) | Inhibitory kaspazy i ich zastosowania | |
| AU2003220437A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
| ZA200600176B (en) | Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| PL369005A1 (pl) | Kombinacje obejmujące inhibitory enzymu COX-2 i aspirynę | |
| ZA200601293B (en) | Proteasome inhibitors and methods of using the same | |
| AU2003210983A1 (en) | Kinase inhibitors and methods of use thereof | |
| EG24845A (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| AU2003257043A8 (en) | Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors | |
| AU2003251513A8 (en) | Rsk inhibitors and therapeutic uses thereof | |
| AU2003245627A8 (en) | Kinases and phosphatases | |
| EP1581496A4 (en) | 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | |
| PL369736A1 (pl) | Nowe kompozycje leków na bazie antycholinergików oraz inhibitorów kinazy EGFR | |
| ZA200501026B (en) | Therapeutic combinations of erb B kinase inhibitors and antineoplastic therapies | |
| EP1569928A4 (en) | THERAPEUTIC COMPOUNDS AND METHOD | |
| AU2003287427A8 (en) | Kinases and phosphatases | |
| AU2003231531A8 (en) | Kinases and phosphatases |